New cell therapy tested for tough blood cancers
Disease control
Completed
This early-phase study tested a new type of cell therapy called RD13-02 in a small group of patients with aggressive blood cancers that had returned or not responded to standard treatments. The main goals were to check if the treatment was safe and to see how the modified immune …
Phase: EARLY_PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC